Edwards Lifesciences Corp. closed 23.74% short of its 52-week high of $96.12, which the company achieved on March 28th.
The OCEANIC-AF trial has raised concerns about factor XI inhibitors. Should physicians still bet on this class of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback